Tag: BriaCell Therapeutics Corp.

April 2, 2019

BriaCell Announces Closing of Upsized & Oversubscribed Non-Brokered Private Placement of $2.97 Million

BriaCell Therapeutics Corp. (TSX:BCT, OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it...
March 26, 2019

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

BriaCell Therapeutics Corp. (TSXV:BCT) (OTC:BCTXF) ("BriaCell" or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer,...
March 25, 2019

BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSXV:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
March 20, 2019

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast...
March 18, 2019

BriaCell Welcomes BioPharma Industry Experts to its Board of Directors

BriaCell Therapeutics Corp. (TSX:BCT, OTC:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces changes...
February 26, 2019

BriaCell Announces C$500,000 Equity Investment by BriaCell Director

BriaCell Therapeutics Corp. (TSXV:BCT) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology,...
February 19, 2019

BriaCell to Present Clinical and Scientific Findings with New Insights at Key Oncology Conferences

BriaCell Therapeutics Corp. (TSX:BCT, OTC:BCTXF) (OTCQB:BCTXF) ("BriaCell" or the "Company"), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy...